| 1 Improvement in symptoms (participant‐assessed at end point) |
2 |
|
Odds Ratio (M‐H, Fixed, 95% CI) |
Subtotals only |
| 1.1 Oestrogen cream versus isoflavone gel |
1 |
50 |
Odds Ratio (M‐H, Fixed, 95% CI) |
2.08 [0.08, 53.76] |
| 1.2 Oestrogen cream versus placebo |
2 |
198 |
Odds Ratio (M‐H, Fixed, 95% CI) |
4.10 [1.88, 8.93] |
| 2 Endometrial thickness |
0 |
|
Odds Ratio (M‐H, Fixed, 95% CI) |
Subtotals only |
| 3 Improvement in symptoms (clinician‐assessed at end point) |
1 |
|
Odds Ratio (M‐H, Fixed, 95% CI) |
Subtotals only |
| 3.1 Oestrogen cream versus placebo |
1 |
153 |
Odds Ratio (M‐H, Fixed, 95% CI) |
3.29 [1.47, 7.36] |
| 4 Improvement in symptoms (decrease in vaginal pH at end point) |
4 |
|
Mean Difference (IV, Fixed, 95% CI) |
Subtotals only |
| 4.1 Oestrogen cream versus non‐hormonal local bio adhesive vaginal moisturiser |
2 |
62 |
Mean Difference (IV, Fixed, 95% CI) |
‐0.36 [‐0.52, ‐0.21] |
| 4.2 Oestrogen cream (21 days) versus placebo (21 days) |
1 |
215 |
Mean Difference (IV, Fixed, 95% CI) |
‐1.20 [‐1.47, ‐0.93] |
| 4.3 Oestrogen cream (twice weekly) versus placebo (twice weekly) |
1 |
208 |
Mean Difference (IV, Fixed, 95% CI) |
‐1.30 [‐1.58, ‐1.02] |
| 4.4 Oestriol gel (50 ug) versus placebo gel |
1 |
153 |
Mean Difference (IV, Fixed, 95% CI) |
‐0.8 [‐1.23, ‐0.37] |
| 5 Improvement in symptoms (increase in maturation indices at end point) |
1 |
|
Mean Difference (IV, Fixed, 95% CI) |
Subtotals only |
| 5.1 Oestrogen cream versus placebo |
1 |
153 |
Mean Difference (IV, Fixed, 95% CI) |
23.7 [17.25, 30.15] |
| 6 Adverse events (breast disorders) |
0 |
|
Odds Ratio (M‐H, Fixed, 95% CI) |
Subtotals only |
| 7 Adverse events (total adverse events) |
1 |
|
Odds Ratio (M‐H, Fixed, 95% CI) |
Subtotals only |
| 7.1 Oestrogen cream versus non hormonal lubricant gel |
1 |
50 |
Odds Ratio (M‐H, Fixed, 95% CI) |
10.67 [0.54, 209.64] |
| 8 Adherence to treatment |
0 |
|
Odds Ratio (M‐H, Fixed, 95% CI) |
Subtotals only |
